🍽️ alprostadil,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Vasodilation: Alprostadil is a synthetic prostaglandin E1 (PGE1) analog that acts as a potent vasodilator. It works by relaxing smooth muscle cells in blood vessels, leading to dilation of arteries and increased blood flow to specific tissues or organs.

  2. Treatment of Erectile Dysfunction (ED): Alprostadil is commonly used to treat erectile dysfunction (ED), a condition characterized by the inability to achieve or maintain an erection sufficient for sexual intercourse. It can be administered through various routes, including intracavernosal injection, intraurethral suppository, or topical cream.

    • Intracavernosal Injection: Alprostadil can be injected directly into the erectile tissue of the penis, leading to rapid onset of erection within minutes. This method is often used in patients who do not respond to oral medications for ED or are unable to use other treatment options.

    • Intraurethral Suppository: Alprostadil can be inserted into the urethra as a suppository using a special applicator. The suppository dissolves and is absorbed through the urethral mucosa, leading to erection within 5 to 15 minutes. This method is less invasive than intracavernosal injection but may be associated with urethral discomfort or irritation.

    • Topical Cream: Alprostadil cream can be applied directly to the glans penis, where it is absorbed through the skin and into the underlying erectile tissue. It typically takes longer to produce an erection compared to injection or suppository forms but may be preferred by some patients due to its convenience and ease of use.

  3. Diagnostic Testing: Alprostadil is also used as a diagnostic agent to assess vascular function in patients with suspected vasculogenic erectile dysfunction. A small dose of alprostadil is injected into the penis, and the resulting erection is evaluated for duration, rigidity, and other parameters to help determine the underlying cause of ED.

  4. Patent Ductus Arteriosus (PDA) Closure: In neonates with certain congenital heart defects, such as patent ductus arteriosus (PDA), alprostadil may be used to keep the ductus arteriosus open or to reopen it if it has closed prematurely. This helps improve blood flow and oxygenation in newborns with critical congenital heart defects.

  5. Side Effects: Common side effects of alprostadil may include penile pain or discomfort, urethral burning or irritation, dizziness, headache, or hypotension (low blood pressure). These side effects are usually mild to moderate in severity and may resolve with continued use or dose adjustments.

  6. Priapism: Priapism, a prolonged and painful erection lasting more than 4 hours, is a rare but serious side effect of alprostadil therapy. Patients should be instructed to seek immediate medical attention if they experience an erection that persists beyond the intended duration or is associated with severe pain or discomfort.

  7. Cardiovascular Effects: Alprostadil can cause systemic vasodilation and hypotension, particularly when administered intracavernosally or intravenously. It should be used with caution in patients with cardiovascular disease, hypotension, or bleeding disorders.

  8. Contraindications: Alprostadil is contraindicated in patients with hypersensitivity to the drug or its components, as well as those with conditions predisposing to priapism, such as sickle cell disease or leukemia.

  9. Drug Interactions: Alprostadil may interact with certain medications, including antihypertensive drugs, anticoagulants, or other agents that affect blood pressure or coagulation. Concomitant use should be carefully monitored, and dosage adjustments may be necessary to minimize the risk of adverse effects.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of alprostadil,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bacteroides uniformis Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by alprostadil,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Clostridium genus Decreases 👪 Source Study Pathogen
Phocaeicola genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Bifidobacterium genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Coprococcus genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bifidobacterium adolescentis species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Mediterraneibacter gnavus species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bacteroides caccae species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bacteroides ovatus species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Streptococcus parasanguinis species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
[Ruminococcus] torques species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Akkermansia muciniphila species Decreases 📓 Source Study High Levels linked to long-lived individuals
Roseburia intestinalis species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study

Impact of alprostadil,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.3 -0.3
ADHD 3.5 0 0
Age-Related Macular Degeneration and Glaucoma 0.3 0.4 -0.33
Allergic Rhinitis (Hay Fever) 1.6 1.7 -0.06
Allergies 3 1.2 1.5
Allergy to milk products 0.9 0.9 0
Alopecia (Hair Loss) 0.8 0.8
Alzheimer's disease 3 2.1 0.43
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.5 0.4 2.75
Ankylosing spondylitis 2.1 1.2 0.75
Anorexia Nervosa 0.4 0.9 -1.25
Antiphospholipid syndrome (APS) 0.6 0.6
Asthma 0.7 0.4 0.75
Atherosclerosis 1.1 0.9 0.22
Atrial fibrillation 1.9 1 0.9
Autism 6.3 5.1 0.24
Barrett esophagus cancer 0.7 0.2 2.5
benign prostatic hyperplasia 0.2 0.2
Biofilm 2 2
Bipolar Disorder 0.7 0.4 0.75
Brain Trauma 0.7 0.2 2.5
Cancer (General) 0.2 3 -14
Carcinoma 2.2 1.9 0.16
Celiac Disease 1.8 2.6 -0.44
Cerebral Palsy 1.2 0.4 2
Chronic Fatigue Syndrome 4.3 4 0.07
Chronic Kidney Disease 1.4 0.5 1.8
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 1.4 0.2 6
Chronic Urticaria (Hives) 1.3 0.3 3.33
Coagulation / Micro clot triggering bacteria 1.1 0.4 1.75
Colorectal Cancer 3.3 0.7 3.71
Constipation 1.1 0.3 2.67
Coronary artery disease 0.9 0.5 0.8
COVID-19 8.6 7.1 0.21
Crohn's Disease 5.5 2.9 0.9
cystic fibrosis 0.5 0.5 0
deep vein thrombosis 0.5 0.2 1.5
Depression 6.1 5 0.22
Dermatomyositis 0.2 0.3 -0.5
Eczema 1 1.4 -0.4
Endometriosis 2 0.5 3
Eosinophilic Esophagitis 0.4 0.3 0.33
Epilepsy 2 2 0
Fibromyalgia 3 1.3 1.31
Functional constipation / chronic idiopathic constipation 3.8 1.7 1.24
gallstone disease (gsd) 1.7 0.8 1.13
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.6 0.6 1.67
Generalized anxiety disorder 1.7 1.5 0.13
giant cell arteritis 0.4 -0.4
Glioblastoma 0.2 -0.2
Gout 0 0
Graves' disease 1.2 0.9 0.33
Halitosis 0.8 0.2 3
Hashimoto's thyroiditis 1.2 0.5 1.4
Hidradenitis Suppurativa 0.6 0.3 1
High Histamine/low DAO 1.6 0.3 4.33
hypercholesterolemia (High Cholesterol) 0.6 0.1 5
hyperglycemia 0.2 1.2 -5
Hyperlipidemia (High Blood Fats) 0.7 0.4 0.75
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 1.6 2.9 -0.81
Hypothyroidism 0.6 -0.6
Hypoxia 0.6 0.6
IgA nephropathy (IgAN) 2.2 -2.2
Inflammatory Bowel Disease 3.4 3 0.13
Insomnia 0.5 0.3 0.67
Intelligence 0.8 0.8
Intracranial aneurysms 0.8 0.4 1
Irritable Bowel Syndrome 2.2 2.9 -0.32
Liver Cirrhosis 3.1 1.7 0.82
Long COVID 6 5.2 0.15
Low bone mineral density 0.2 -0.2
Lung Cancer 0.6 0.6 0
Mast Cell Issues / mastitis 0.3 0.3 0
ME/CFS with IBS 1.2 1.5 -0.25
ME/CFS without IBS 1.1 1.3 -0.18
Menopause 1.7 1.7
Metabolic Syndrome 5.3 5.8 -0.09
Mood Disorders 7.9 5 0.58
multiple chemical sensitivity [MCS] 0.8 0.2 3
Multiple Sclerosis 3.2 2.3 0.39
Multiple system atrophy (MSA) 0.7 0.6 0.17
neuropathic pain 0.7 -0.7
Neuropathy (all types) 0.4 0.2 1
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.6 2.9 -0.81
NonCeliac Gluten Sensitivity 1 0.5 1
Obesity 5.5 3 0.83
obsessive-compulsive disorder 3.8 2 0.9
Osteoarthritis 2.3 2.3
Osteoporosis 1 0.5 1
pancreatic cancer 0.3 0.3
Parkinson's Disease 4.1 3.7 0.11
Polycystic ovary syndrome 2 1 1
Postural orthostatic tachycardia syndrome 0.4 0.3 0.33
Premenstrual dysphoric disorder 0.9 0.4 1.25
primary biliary cholangitis 0.3 0.8 -1.67
Psoriasis 3.2 0.7 3.57
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.3 2.6 0.65
Rosacea 0.5 0.5 0
Schizophrenia 5.1 1 4.1
scoliosis 0 0.2 0
Sjögren syndrome 1.9 2.5 -0.32
Sleep Apnea 1 0.4 1.5
Slow gastric motility / Gastroparesis 0.7 0.3 1.33
Small Intestinal Bacterial Overgrowth (SIBO) 0.9 0.6 0.5
Stress / posttraumatic stress disorder 2.4 1 1.4
Systemic Lupus Erythematosus 2.7 0.9 2
Tic Disorder 0.9 1 -0.11
Tourette syndrome 0 0.1 0
Type 1 Diabetes 2 2.2 -0.1
Type 2 Diabetes 5.7 4.4 0.3
Ulcerative colitis 2.1 3.1 -0.48
Unhealthy Ageing 4.2 0.6 6
Vitiligo 0.7 1.2 -0.71

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]